Alongside opening the new offices, Roche Diagnostics capabilities in China have been further recognised as it has been ...

The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

On November 8, 2024, Roche Diagnostics enhanced the company's long term commitment to China's local healthcare industry, to ultimately benefit patients in China and beyond, with the opening of its ...

Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...

Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...

Healthcare solutions provider Qure.ai has entered into a collaboration with Roche Diagnostics Asia Pacific’s Startup Creasphere (APAC) initiative to work on AI-driven medical imaging technologies.

Presented at the Clinical Trials in Alzheimer’s Disease congress, being held in Madrid, Spain, Roche’s diagnostics unit showed that a negative result from one test—its Elecsys amyloid plasma ...

Data from two Alzheimer’s tests being developed by Roche Holding AG showed high accuracy in detecting the disease in patients being tested for the condition. The tests measure biomarkers in the blood ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.